ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Accelerating The Development Of Oncology Medicines

  Oncology drug development has seen a significant shift in focus, as molecule chemistries and drug technologies have improved. Explore five areas for consideration and the potential emerging solutions.

• Key Offerings To Support Your OSD On Its Journey To Market

  Examine several important factors needed to effectively support oral solid dosage therapeutic manufacturing and overcome the complexities involved.

• Reducing Environmental Impact At All Stages Of The Medicine Journey

  Explore how utilizing technologies like AI and digital twinning can inform decision-making at the R&D stage and how to optimize the delivery of the final drug product to patients with greener logistics.

• Why It Is Never Too Early To Consider Tungsten Interactions

  A key challenge to sensitive biotechnological or biologic drugs, especially proteins, is the potential presence of tungsten and tungsten oxides from the syringe forming process.

• From Regulators To PUPSIT: Notes On Annex 1 Revision Implementation

  Kevin Smyth, a biochemical engineer with 30 years of experience in the pharmaceutical industry, offers insights and expertise in working with firms to understand what regulators seek to meet new standards.

• Container Selection For A Highly Sensitive Drug Product: A Success Story

  Learn about the importance of selecting the right container for sensitive drug products and how close collaboration is crucial for avoiding commercialization delays and safety risks to patients.

• Sample Sizes For Performance Testing Of Combination Products, Packaging

  When developing combination products or evaluating primary packaging for drug products one must evaluate the performance of the devices and the packaging to ensure that they are fit-for-purpose.

• Engineering Advances In Needle Geometry To Accommodate Viscous Biologics

  Explore the challenges faced in administering highly viscous biologics to patients via subcutaneous injection and how new special thin-wall needles are able to tackle them.

• CMO As Partners For ADC Process Development, Scale-Up, Optimization

  ADC programs can accelerate through clinical phases rapidly, making early preparation for commercial launch imperative. It's sensible to partner with a CMO with a strong biologics foundation.

• Overcoming A Failed Design Verification Test For Your Delivery Device

  If a drug delivery device fails a design verification test, the consequences can be lost revenue for the pharma company and delays for patients. Explore how to eliminate design verification failure.